News headlines about Akebia Therapeutics (NASDAQ:AKBA) have trended positive recently, Alpha One reports. The research group, a division of Accern, identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Akebia Therapeutics earned a daily sentiment score of 0.36 on Alpha One’s scale. Alpha One also assigned media headlines about the biopharmaceutical company an impact score of 91 out of 100, meaning that recent press coverage is extremely likely to have an effect on the company’s share price in the near term.
These are some of the media headlines that may have effected AlphaOne’s analysis:
- Riding the Upswing: Akebia Therapeutics, Inc. (NASDAQ:AKBA) vs. Franklin Financial Network, Inc. (:FSB) – Geneva Journal (genevajournal.com)
- Akebia Basks in Vifor Deal (leisuretravelaid.com)
- Why These Stocks Remain in Focus? – Triumph Group, Inc. (TGI), Akebia Therapeutics, Inc. (AKBA) – StockNewsMagazine (stocknewsmagazine.com)
- Vifor Pharma agrees to sell HIF stabilizer to Fresenius Medical Care North America (nephrologynews.com)
- Favorable News Coverage Extremely Likely to Affect Akebia Therapeutics (AKBA) Share Price (nyhetsbanken.info)
Akebia Therapeutics (NASDAQ:AKBA) last announced its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by $1.00. The company had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $16.50 million.
AKBA has been the subject of a number of research reports. Zacks Investment Research downgraded Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 28th. Aegis reiterated a “buy” rating and set a $21.00 price target on shares of Akebia Therapeutics in a research report on Tuesday, February 14th. Needham & Company LLC reiterated a “buy” rating and set a $21.00 price target (up from $18.00) on shares of Akebia Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “neutral” rating and set a $25.00 price target (up from $21.00) on shares of Akebia Therapeutics in a research report on Wednesday. Finally, JMP Securities lifted their price target on Akebia Therapeutics from $19.00 to $21.00 and gave the company an “outperform” rating in a research report on Wednesday, April 26th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.57.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).
Receive News & Ratings for Akebia Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.